Stabilized HIV Env Trimer Vaccines for Broad Neutralizing Antibodies

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing HIV vaccines struggle to elicit a broad, robust immune response against diverse HIV Env polypeptides, particularly in producing biochemically stable trimeric Env immunogens that induce diverse neutralizing antibody responses.

Innovation Solution

Development of an HIV Env glycoprotein with specific amino acid sequences and stabilized trimers, along with recombinant vectors and host cells, to produce polyclonal antibodies that specifically target the V2 region, enhancing immune response and neutralizing antibody production.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If conventional HIV Env immunogens are used, then vaccine development can proceed with existing methods, but the ability to elicit broad neutralizing antibody responses against diverse HIV strains is insufficient

Engineering Contradiction:

Improvebreadth of immune response against diverse HIV strainsVSAvoidbiochemical stability of trimeric Env immunogens

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent applies local quality by making specific amino acid substitutions at particular positions within the Env polypeptide sequence (e.g., positions in the V2 loop and other variable regions) while maintaining the overall trimeric structure. This allows the immunogen to present diverse epitopes for broad antibody recognition while preserving the stable trimeric scaffold that ensures biochemical reliability.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent employs parameter changes by modifying the amino acid sequence parameters of the Env polypeptide through specific substitutions, deletions, or additions at defined positions. These sequence parameter changes enable the immunogen to elicit broader neutralizing antibody responses against diverse HIV strains while maintaining trimeric structural stability through careful selection of substitutions that preserve folding and assembly properties.

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If the Env polypeptide sequence is highly variable to cover diverse HIV strains, then the breadth of immune response increases, but the biochemical stability of the trimeric structure decreases

Engineering Contradiction:

Improvecoverage of diverse HIV strainsVSAvoidtrimeric structure stability

Core Design Contradiction:

Adaptability or versatilityVSStability of the object's composition

Solution Approach 1:

The patent applies segmentation by dividing the Env polypeptide into distinct functional regions: variable regions (such as V1, V2, V3 loops) that are modified to increase diversity and epitope variability, and conserved regions (such as the transmembrane domain and core structural elements) that are maintained to preserve trimeric structure stability. This segmentation allows independent optimization of diversity and stability in different parts of the molecule.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

Inventive Principle:

Principle #3Local quality

3Productivity

If existing HIV vaccine antigens are used, then vaccine production can proceed with current methods, but the elicitation of robust and diverse B cell responses is insufficient

Engineering Contradiction:

Improveproduction of neutralizing antibodiesVSAvoiddiversity of B cell responses

Core Design Contradiction:

ProductivityVSAdaptability or versatility

Solution Approach 1:

The patent applies universality by designing the stabilized Env trimer to serve multiple functions simultaneously: it maintains the native trimeric structure for high immunogenicity, incorporates diverse variable regions for broad epitope coverage, and includes stabilizing mutations for enhanced biochemical stability. This multi-functional design enables a single immunogen to elicit diverse B cell responses across multiple HIV strains while maintaining robust production characteristics.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentEP3526236B1Signature-based human immunodeficiency virus (HIV) envelope (ENV) trimer vaccines and methods of using the same

Publication Date: 2025.12.10 TRIAD NATIONAL SECURITY LLC

Figure 1A~1B
Figure 2A~2G
Figure 3A~3B

AI summary

The invention features immunogenic compositions and vaccines containing an optimized human immunodeficiency virus (HIV) envelope (Env) polypeptide (e.g., a stabilized trimer of optimized HIV Env polypeptides) or a polynucleotide encoding an optimized HIV Env polypeptide and uses thereof. The invention also features methods of treating and/or preventing a HIV infection by administering an immunogenic composition or vaccine of the invention to a subject (e.g., a human).